Abstract:Protein farnesyltransferase inhibitors (FTIs) have shown clinical responses in hematologic malignancies, but the mechanisms are unclear. To better understand potential mechanisms of action, we have studied effects of the FTI tipifarnib on inflammatory responses in vitro and in vivo. In a human leukemia cell line THP-1, tipifarnib inhibited lipopolysaccharide (LPS)-induced transcription of chemokines [monocyte chemotactic protein (MCP)-1 and MCP-2], cytokines [interleukin (IL)-1β, IL-6, and interferon (IFN)β], signaling molecules (MyD88 and STAT-1), proteases [matrix metalloproteinase (MMP-9)], and receptors (urokinase receptor). Tipifarnib also inhibited LPS-induced secretion of MMP-9, IL-6, MCP-1, and IL-1β in THP-1 cells. In primary human peripheral blood mononuclear cells, dose-dependent inhibition of LPS-induced tumor necrosis factor (TNF)-α, IL-6, MCP-1, and IL-1β by tipifarnib was observed with no evidence of cytotoxicity. Similar results were obtained in vivo in a murine model of LPS-induced inflammation, where pretreatment with tipifarnib resulted in significant inhibition of TNF-α, IL-6, MCP-1, IL-1β, and MIP-1α production. Tipifarnib had no effect in vitro or in vivo on LPS-induced IL-8. Studies in THP-1 cells to address potential mechanism(s) showed that tipifarnib partially inhibited LPS-induced p38 phosphorylation. Tipifarnib significantly inhibited inhibitory subunit of nuclear factor-κB (NF-κB) (IκB)-α degradation and p65 nuclear translocation induced by LPS, but not by tumor necrosis factor-α, IL-1α, or toll-like receptor (TLR)2 ligand, suggesting that the target for inhibition of NF-κB activation was exclusive to the LPS/TLR4 signal pathway. The extent of IκB-α degradation inhibition did not correlate with inhibition of Ras farnesylation, indicating that Ras was not the target for the observed anti-inflammatory activity of tipifarnib. Our findings differ from those for other FTIs, which may have relevance for their dissimilar activity in specific tumor repertoires.

Effects of farnesyl transferase inhibitor in anti-tumor and multidrug resistance

Recent Advances In Understanding The Antineoplastic Mechanisms Of Farnesyltransferase Inhibitors

New Tricks for Human Farnesyltransferase Inhibitor: Cancer and Beyond.

Inhibition of farnesyltransferase reduces angiogenesis by interrupting endothelial cell migration.

The Recent Development of Farnesyltransferase Inhibitors As Anticancer and Antimalarial Agents.

Inhibition of Expression of Vascular Endothelial Growth Factor and Its Receptors in Pulmonary Adenocarcinoma Cell by TNP-470 in Combination with Gemcitabine

Autophagy induced by farnesyltransferase inhibitors in cancer cells.

Advances in the treatment of tumors with focal adhesion kinase inhibitors

Blocked pathways: FTIs shut down oncogene signals.

The discovery of a novel compound with potent antitumor activity: virtual screening, synthesis, biological evaluation and preliminary mechanism study

Therapeutic Potential of Fucosyltransferases in Cancer and Recent Development of Targeted Inhibitors

Ras inhibitor farnesylthiosalicylic acid conjugated with IR783 dye exhibits improved tumor-targeting and altered anti-breast cancer mechanisms in mice

Farnesyltransferase-inhibitors exert in vitro immunosuppressive capacity by inhibiting human B-cells

Farnesyltransferase inhibitors-induced autophagy: alternative mechanisms?

Anti-Inflammatory Activity in Vitro and in Vivo of the Protein Farnesyltransferase Inhibitor Tipifarnib

Recent advances of dual FGFR inhibitors as a novel therapy for cancer

Targeting FGFRs for Tumor Therapy: Current Status and Novel Strategies

Discovery of Novel Inhibitors for Human Farnesyltransferase (hftase) Via Structure-Based Virtual Screening

Fumitremorgin C Reverses Multidrug Resistance in Cells Transfected with the Breast Cancer Resistance Protein

Farnesyltransferase Inhibitors Induce Dna Damage Via Reactive Oxygen Species in Human Cancer Cells